Patent for Novoclem’s Cystic Fibrosis treatment

Novoclem Therapeutics announced that US Patent No. 9,850,322 — “Water Soluble Nitric Oxide-Releasing Polyglucosamines and Uses Thereof” has been issued.

The patent lists Mark Schoenfisch and Yuan Lu as inventors and is assigned to the University of North Carolina at Chapel Hill.

It is exclusively licensed to Novoclem Therapeutics for the treatment of respiratory diseases.

The patent covers Novoclem’s lead inhalable drug candidate, BIOC51, which has been designated as a “Qualified Infectious Disease Product” (QIDP) by the US Food & Drug Administration for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.

“Obtaining this patent is an important milestone in our journey towards building out our nitric oxide-releasing product pipeline,” said Schoenfisch, Professor of Chemistry at the University of North Carolina at Chapel Hill, co-inventor of the nitric oxide-releasing technology and Novoclem’s chief scientific officer.

“Having a water soluble, tunable system for releasing nitric oxide created a new paradigm for treating disease with nitric oxide giving us an ability to deliver nitric oxide to a much broader range of locations within the body.”

Novoclem CEO Anne Whitaker said: “Our intellectual property portfolio has steadily grown through both internal and partnered efforts, but issuance of this patent is particularly satisfying.

“This technology is foundational, so having it transition from ‘patent pending’ to an issued patent puts us in a better position to engage investors and partners – we are confident about this technology helping those living with Cystic Fibrosis (CF).”